Perez HC, González-Fernández N, Moreira-Rubio A, Zamora-Sánchez J, Pérez-González E, Bricaud M, Gaucheron J, Alfaro-Martínez A, Salinas-Rodríguez D, Sardiñas-Padrón M, Domingo-Puentes M, Segura-Silva R

Language: English
References: 0
Page: 4201-4205
PDF size: 283.64 Kb.

ABSTRACT

Infestations with cattle tick (Rhipicephalus microplus) have an economic impact by reducing animal weight gain and milk production. An alternative for tick control in cattle is the use of Gavac^® vaccine, which contains the Bm86 antigen as active pharmaceutical ingredient. In this work, Montanide^™ ISA 50 V2 was evaluated as adjuvant for Gavac^® to homogenize the formulation process. The current adjuvant (mineral oil), the proposed Montanide^™ ISA 50 V2 and the emulsion formed were subjected to physicochemical characterizations. The results confirmed that both adjuvants were physicochemically similar and the derived emulsions exhibited better characteristics when using Montanide^™ ISA 50 V2. The three batches studied 24 months for stability showed results analytically consistent with the expected ones, confirming that Gavac^® immunogen is stable for two years. Until October 2017, nine vaccine batches equivalent to 1.5 million doses were obtained containing Montanide^™ ISA 50 V2 as a new variant of vaccine adjuvant formulation. Those batches were compared with historical data, showing similar qualitative and biological activity properties. Therefore, it was proposed that the use of Montanide^™ ISA 50 V2 as adjuvant for the Bm86 antigen formulation of the Gavac^® vaccine provides better qualitative physicochemical characteristics, to be corroborated in vaccination trials in cattle.